As of June 14, 2019, we have raised $745,000 towards the total of $2 M seed round.

Key Members on Our Team:

Founders

Jon Northrup

CEO & Co-Founder

Mr. Northrup brings broad experience to Stingray, having worked at Eli Lilly and Company as an executive in Finance, Marketing, Sales, Corporate Business Development and Corporate Strategy; in management consulting with Asian companies, and in founding the venturing group with Jubilant Life Sciences.

Mr. Northrup is a Certified Licensing Professional in the Licensing Executive Society, received his MBA from the Wharton School of the University of Pennsylvania in Finance, and received his BA in Economics from Northwestern University.

Sunil Sharma, MD FACP

Chief Medical Officer, Co-Founder, Inventor

Dr. Sharma is the Jon and Karen Huntsman Presidential Professor for Cancer Research, Deputy Center Director, at the Huntsman Cancer Institute at the University of Utah. Dr. Sharma has conducted over 150 clinical trials over the past 15 years. 

Dr. Sharma started the G/I oncology investigational program at the Nevada Cancer Institute in Las Vegas and was in charge of several new drugs and their development with Novartis. Dr. Sharma has also worked at Sloan Kettering Memorial Hospital, one of the most prestigious cancer hospitals in the world. 

Key Scientists

Sunil Sharma, MD FACP

Chief Medical Officer, Co-Founder, Inventor

Dr. Sharma is the Jon and Karen Huntsman Presidential Professor for Cancer Research, Deputy Center Director, at the Huntsman Cancer Institute at the University of Utah. Dr. Sharma has conducted over 150 clinical trials over the past 15 years. 

Dr. Sharma started the G/I oncology investigational program at the Nevada Cancer Institute in Las Vegas and was in charge of several new drugs and their development with Novartis. Dr. Sharma has also worked at Sloan Kettering Memorial Hospital, one of the most prestigious cancer hospitals in the world. 

Mohan Kaadige, PhD

Head of Biology

Dr. Kaadige is a research scientist with a deep passion for understanding the mechanisms and signaling pathways involved in the development and progression of cancer. At TGen, Dr. Kaadige works closely with Dr. Sharma and Dr. Vankayalapati to develop targeted cancer therapy programs. The team uses a combination of computational drug design, synthetic chemistry and biology to discover small molecule inhibitors for cancer therapy. Dr. Kaadige applies his skills to investigate proof of mechanism for novel inhibitors.

 

Hari Vankayalapati, PhD

Monil Shah, Pharm D, MBA

And More...

Business & Operation

Scott Jordan

Chief Financial Officer

Mr. Jordan is an accomplished life sciences professional with more than 25 years of investment banking and corporate experience in negotiating strategic corporate alliances, securing international licensing agreements, building national sales teams, and contributing to successful product development, approval and launch. Prior to joining Stingray, Scott was an investment banker with Healthios Capital Markets and employed in business development and commercialization roles with NeoPharm, Akorn Ophthalmics, and Abbot Laboratories

Mr. Jordan earned a BA from Michigan State University, Masters of Business Administration from Kellstadt Graduate School of Management (DePaul).

Uma Bhatt, CPA

Chief Accounting Officer

Ms. Bhatt is a professional CPA with extensive hands on and executive management experience as a CFO, COO, Corporate Controller, SEC Reporting with international experience of Controllership, Business Development Executive, Internal Audit, Tax, Sarbanes-Oxley, SEC Reporting, Project Manager and Risk Management.

Advisors

Dan Von Hoff, MD, FACP

Clinical Advisor

Michael Berens, PhD

Brain Tumor Advisor

Joanne Tan

Brand Advisor

Wood Phillips

IP

JP Morgan Chase

Banking

Wilson, Sonsini, et. al

Attorneys

Headquarters:

Texas Medical Center 2450 Holcombe Blvd., Suite X Houston, TX 77021 Jon@stingraytx.com

General Inquiries:

Get in touch and we’ll get back to you as soon as we can. Thanks.